Evidence map›Paper›PMID 37219785›Full record

ReviewDrug safety2023

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance.

Priya Bahri, Geoffrey Bowring, Brian D Edwards, Christopher Anton, Jeffrey K Aronson, Angela Caro-Rojas, Bruce P J Hugman, Peter G Mol, Gianluca Trifirò, Katarina Ilic and 14 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Priya BahriSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland. priya.bahri@ema.europa.eu.ORCID 0000-0002-7798-6117
Geoffrey BowringSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Brian D EdwardsSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Christopher AntonSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Jeffrey K AronsonCentre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK.
Angela Caro-RojasSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Bruce P J Hugman, Oxford, UK.
Peter G MolSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Gianluca TrifiròDepartment of Diagnostics and Public Health, University of Verona, Verona, Italy.
Katarina IlicSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Riadh DaghfousTunisian National Centre of Pharmacovigilance, Tunis, Tunisia.
Irene FermontIsrael Society for Medication and Vaccine Safety (ERANIM), Jerusalem, Israel.
Giovanni FurlanSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
Wolfgang GaissmaierDepartment of Psychology, Social Psychology and Decision Sciences, University of Konstanz, Konstanz, Germany.
Mohammad Ishaq GeerDepartment of Pharmaceutical Sciences, University of Kashmir, Srinagar, India.
Kenneth Y Hartigan-GoSpecial Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG), Geneva, Switzerland.
François HouÿezEuropean Organisation for Rare Diseases (EURORDIS), Paris, France.
Hansjörg NethDepartment of Psychology, Social Psychology and Decision Sciences, University of Konstanz, Konstanz, Germany.
Gediminas NorgelaUppsala Monitoring Centre (UMC), Uppsala, Sweden.
Yaowares OppamayunThai Food and Drug Administration, Health Product Vigilance Center, Bangkok, Thailand.
D K Theo RaynorSchool of Healthcare, University of Leeds, Leeds, UK.
Mehdi BouhlelTunisian National Centre of Pharmacovigilance, Tunis, Tunisia.
Federica SantoroUppsala Monitoring Centre (UMC), Uppsala, Sweden.
Janet SultanaPharmacy Department, Mater Dei Hospital, Msida, Malta.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPharmacovigilanceAdverse Drug Reaction Reporting SystemsHumansPublic OpinionSocieties

Identifiers

PMID37219785
PMCPMC10203670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.